← Trials/Trial dossier/NCT03413319

CompletedPhase 1

Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104

Lead sponsor

AbbVie

Asset

Tilavonemab

Listed sites

Recruiting sites

Enrollment

actual

Study population

Frontotemporal dementia

Key I/E criterion

•Age ≥18

Primary endpoint

•Adverse Events

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDM16-948

NCT IDNCT03413319

Timeline

Milestones

Study first posted2018-01-29actual

Study start2018-04-17actual

Primary completion2019-11-20actual

Study completion2019-11-20actual

Last update posted2019-12-03actual

Assets

Drug assets

Tilavonemab

Study populations

Who this study enrolls

Frontotemporal dementia

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Subject completed Study C2N-8E12-WW-104 (NCT02494024)

•Subject was not eligible to enroll in Study M15-562 (NCT02985879)

Exclusion criteria

•Subject weighs less than 35 kg at screening

•Subject has any contraindication or inability to tolerate brain MRI

•Subject has any significant change in his/her medical condition that could interfere with the subject's participation in the study, could place the subject at increased risk, or could confound interpretation of study results

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

1 endpoint

Primary/protocol endpoint

Adverse Events

Time frame:From first dose of study drug to 20 weeks after last dose of study drug (up to 2 years, 5 months)

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.